O Shaughnessy Asset Management LLC purchased a new position in shares of Bausch Health Companies Inc (NYSE:BHC) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm purchased 1,176,604 shares of the company’s stock, valued at approximately $29,915,000. O Shaughnessy Asset Management LLC owned about 0.34% of Bausch Health Companies at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently bought and sold shares of the company. NEXT Financial Group Inc bought a new stake in shares of Bausch Health Companies in the 3rd quarter worth approximately $101,000. Steward Partners Investment Advisory LLC bought a new stake in shares of Bausch Health Companies in the 3rd quarter worth approximately $106,000. Polaris Greystone Financial Group LLC bought a new stake in shares of Bausch Health Companies in the 3rd quarter worth approximately $107,000. Quadrant Capital Group LLC bought a new stake in shares of Bausch Health Companies in the 3rd quarter worth approximately $118,000. Finally, Bedel Financial Consulting Inc. bought a new stake in shares of Bausch Health Companies in the 3rd quarter worth approximately $129,000. Institutional investors and hedge funds own 42.90% of the company’s stock.
NYSE BHC opened at $27.20 on Friday. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.89 and a current ratio of 1.14. Bausch Health Companies Inc has a twelve month low of $13.86 and a twelve month high of $28.45. The company has a market cap of $9.48 billion, a P/E ratio of 7.10, a PEG ratio of 0.37 and a beta of -0.28.
Bausch Health Companies (NYSE:BHC) last released its quarterly earnings results on Tuesday, November 6th. The company reported $1.15 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.84 by $0.31. Bausch Health Companies had a positive return on equity of 32.19% and a negative net margin of 40.41%. The company had revenue of $2.14 billion for the quarter, compared to analyst estimates of $2.09 billion. The firm’s quarterly revenue was down 3.7% compared to the same quarter last year. Research analysts predict that Bausch Health Companies Inc will post 3.7 EPS for the current fiscal year.
In other news, CFO Paul Herendeen purchased 10,000 shares of the company’s stock in a transaction that occurred on Friday, September 14th. The shares were bought at an average cost of $22.61 per share, for a total transaction of $226,100.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Schutter Richard U. De purchased 125,000 shares of the company’s stock in a transaction that occurred on Thursday, September 13th. The shares were purchased at an average price of $23.96 per share, for a total transaction of $2,995,000.00. The disclosure for this purchase can be found here. Insiders have purchased 165,000 shares of company stock worth $3,890,700 over the last 90 days. 11.54% of the stock is currently owned by corporate insiders.
A number of equities research analysts have recently weighed in on BHC shares. Piper Jaffray Companies set a $13.00 price objective on Bausch Health Companies and gave the stock a “sell” rating in a research report on Monday, July 23rd. Wells Fargo & Co reiterated a “sell” rating on shares of Bausch Health Companies in a research report on Monday, August 6th. Mizuho reiterated a “buy” rating and issued a $31.00 price objective on shares of Bausch Health Companies in a research report on Tuesday, August 7th. Cantor Fitzgerald reiterated a “buy” rating and issued a $32.00 price objective on shares of Bausch Health Companies in a research report on Tuesday, August 7th. Finally, JPMorgan Chase & Co. lifted their price objective on Bausch Health Companies to $18.00 and gave the stock an “underweight” rating in a research report on Wednesday, August 8th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company. Bausch Health Companies presently has an average rating of “Hold” and a consensus price target of $27.55.
About Bausch Health Companies
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.
Featured Story: Stock Symbols Definition, Examples, Lookup
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.